Liver transplantation for hepatitis B virus. Pre-emptive and peri-operative prophylaxis

Digestive and Liver Disease

Volumn 41, Issue SUPPL. 2, 2009, Pages

  Mas, A ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Adefovir; Anti HBs immunoglobulins; Cirrhosis; Lamivudine; Liver transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; LAMIVUDINE; NIULIVA; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; GRAFT INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER GRAFT; LIVER INJURY; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; PERIOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECURRENCE RISK; REINFECTION; RISK REDUCTION; SURVIVAL RATE; VIRUS MUTANT; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; PERIOPERATIVE CARE; PHOSPHONIC ACIDS; POSTOPERATIVE COMPLICATIONS; RECURRENCE; TREATMENT OUTCOME;

EID: 66149124109     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(09)60443-6     Document Type: Article

References (20)

1. Shouval D., and Samuel D. Hepatitis immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 32 (2000) 1189-1195
2. Roche B., and Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 1, hepatitis B. Transpl Int 17 (2005) 746-758
3. Tan J., and Lok A. Antiviral therapy for pre- and post-liver transplantation patients with hepatitis B. Liver Transpl 13 (2007) 323-326
4. Lok A. Liver transplantation for patients with lamivudine-resistant HBV: what is the optimal prophylactic strategy?. Liver Transpl 11 (2005) 490-493
5. Samuel D., Muller R., Alexander G., Fassati L., Ducot B., Benhamou J.P., et al. Liver transplantation in European patients with the hepatitis B surface antigen. New Eng J Med 329 (1993) 1842-1847
6. Villamil F.G. Prophylaxis with anti-HBs immune globulins and nu-cleoside analogues after liver transplantation for HBV infection. J Hepatol 39 (2003) 466-474
7. Restrepo J.C., Rimola A., Mas A., Navasa M., Salmerón J.M., Cirera I., et al. Administración prolongada de gammaglobulina hiperinmune antihepatitis B en pacientes con trasplante hepático por hepatopatía por virus de la hepatitis B. Gastroenterol Hepatol 19 (1996) 491-496
8. Cirera I., Mas A., Salmerón J.M., Jiménez D.F., Sanjosé A., Navasa M., et al. Reduced doses of hepatitis B immunoglobulin protect against hepatitis B virus reinfection recurrence after liver transplantation. Transpl Proc 33 (2001) 2551-2553
9. Rosenau J., Kreutz T., Kujawa M., Bahr M.J., Rifai K., Hooman N., et al. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol 46 (2007) 635-644
10. Perrillo R.P., Wright T., Rakela J., Levy G., Schiff E., Gish R., et al. Multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33 (2001) 424-432
11. Fontana R.J., Keeffe E.B., Carey W., Fried M., Reddy R., Kowdley K.V., et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 8 (2002) 433-439
12. Yao F.Y., Terrault N.A., Freise C., Maslow L., and Bass N.M. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B virus infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34 (2001) 411-416
13. Marzano A., Lampertico P., Mazzaferro V., Carenzi S., Vigano M., Romito R., et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 11 (2005) 532-538
14. Bárcena R., del Campo S., Moraleda G., Casanovas T., Prieto M., Buti M., et al. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transplant Proc 37 (2005) 3960-3962
15. Schiff E., Lai C.L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 13 (2007) 349-360
16. Schreibman I.R., and Schiff E.R. Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 5 (2006) 1-8
17. Grellier L., Mutimer D., Ahmed M., Brown B., Burroughs A.K., Rolles K., et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348 (1996) 1212-1215
18. Mutimer D., Dusheiko G., Barrett C., Grellier L., Ahmed M., An-schuetz G., et al. Lamivudine without HBIG for prevention of graft reinfection by hepatitis B: long-term follow up. Transplantation 70 (2000) 809-815
19. Buti M., Mas A., Prieto M., Casafont F., González A., Miras M., et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine wih long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 38 (2003) 811-817
20. Buti M., Mas A., Prieto M., Casafont F., González A., Miras M., et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Transplantation 84 (2007) 650-654